Illumina CFO Goswami to leave, Summit Therapeutics’ Dhingra named successor
![Illumina CFO Goswami to leave, Summit Therapeutics’ Dhingra named successor](https://tiafx.com/wp-content/uploads/2024/04/828-LYNXNPEC0D0AP_L.jpg)
(Tiafx) – Illumina (NASDAQ:ILMN) said on Tuesday Chief Monetary Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by feeble Summit Therapeutics (NASDAQ:SMMT)’ executive Ankur Dhingra.
Goswami, who has more than twenty years of experience in the life sciences change, used to be the CFO since early 2023 and must support as an adviser till June 30, the corporate said.
Illumina has also reaffirmed its forecast for the first quarter and entire-year 2024.